Biotech company Fibrocell Science (OTCBB: FCSC) announced Wednesday that the US FDA has accepted for review the company's submission for azficel-T, or laViv, a treatment for laugh lines and wrinkles.
The news sent the company's stock price up by more than 21% as of 1:15pm EST on Wednesday, to trade at $0.73.
The company's approach works to replenish the patient's own fibroblasts, the cells that are responsible for releasing collagen, elastin and hyaluronic acid, which add strength and elasticity to the skin. During the treatment, a patient's own natural fibroblasts are extracted, multiplied and re-injected to regenerate skin.
"We are pleased that our complete response was accepted and look forward to working closely with the FDA through the review process," said chairman and CEO David Pernock.
"If approved, azficel-T will be the first and only personalized cell-based aesthetic treatment."
The company said it is planning to conduct studies on applying its fibroblast technology in additional areas, and for the treatment of restrictive burn scars, acne scars, and periodontal disease.
Fibrocell also recently submitted a clinical study report to the FDA for a Phase II/III trial of azficel-T in acne scarring.